Skip to content

Bio-Rad Laboratories BIO Price / earnings

Price / earnings at other companies

Abbott logo
AbbottABT
28.4×+11.4×
Becton, Dickinson and Company logo
Becton, Dickinson and CompanyBDX
39.3×-4.6×
Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
26.7×-2.2×
Danaher logo
DanaherDHR
36.4×-2.6×
Revvity logo
RevvityRVTY
40.9×-3.5×
Agilent Technologies logo
Agilent TechnologiesA
23.1×-3.1×

Other financials

Income statement

See full
Revenue$592.1M+1.1%
Gross profit$309.4M+1.1%
Operating income$34.1M+43.9%
Net income-$527.1M-924%
EPS (diluted)-$19.55-954%

Balance sheet

See full
Cash & equivalents$509.0M-2.7%
Total debt$987.3M-28.4%
Total equity$6.9B+2.6%
Total assets$9.8B+2.8%

Cash flow

See full
Operating cash flow$108.1M-16.8%
CapEx$30.0M-12.8%
Free cash flow$78.1M-18.2%

Valuation

See full
Market cap$7.56B+10.3%
Enterprise value$8.04B+4.2%
P/S2.9×+0.2×

Profitability

See full
Gross margin51.9%-1.6pp
Operating margin8.8%-3.1pp
Net margin6.5%+3.4pp
FCF margin13.8%-0.2pp

Returns & leverage

See full
Return on equity2.5%+1.3pp
Debt / equity0.1×-0.1×
Current ratio3.2×-2.8×

Where this comes from

Calculated from Bio-Rad Laboratories’s reported figures.

Based on the most recent quarter.

The official record: Bio-Rad Laboratories’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bio-Rad Laboratories's price / earnings.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Bio-Rad Laboratories's price / earnings?
Bio-Rad Laboratories (BIO) reported price / earnings of 44.6× in Q1 2026.
What is the long-term trend for Bio-Rad Laboratories's price / earnings?
Over 2 years (2020 to 2025), Bio-Rad Laboratories's price / earnings has grown at a 53.2% compound annual growth rate (CAGR), from 4.6× to 10.8×.
What does price / earnings mean?
How many dollars investors pay for each dollar of the company's annual profit.
How do you interpret price / earnings?
Lower can mean cheaper — or that the market expects earnings to fall. High multiples embed growth expectations. Meaningless when earnings are negative, so it is suppressed there.
How does price / earnings compare across companies?
Compare against the company's own history and sector peers, not across sectors with different growth and risk profiles.